SBIR/STTR Research Award

Characterization of a cell line for use as a reference standard for human embryon

Award identifier 3f745efbb2d55de56c76778d3409fda92d01e06015fc6e69c4a1a3e4d457ef89Awarding agency Department of Health and Human Services · National Institutes of Health

Award amount

$107,450

Program and phase

SBIR · Phase I

Award year

2008

Explore This Research Award in CaptureIQ

Research the technology, evaluate the recipient and agency, identify related opportunities, and explore potential follow-on work with CaptureIQ.

Award details

Awarding agency
Department of Health and Human Services
Branch
National Institutes of Health
Recipient company
GLOBALSTEM, INC.
Proposal award date
Not reported
Contract end date
Not reported
UEI
Not reported
Solicitation number
PHS2007-2
Topic code
Not reported

Research abstract

DESCRIPTION (provided by applicant): Human embryonic stem cell (hESC) research has a great potential to further our understanding of basic mechanisms of human development and may lead to the development of novel therapeutics. Absent from this young field h as been the acceptance and use of reference standard cell lines. Uniform use of a reference standard would permit investigators to reliably compare results across laboratories and would aid in building sequential advances in the field. A reference cell lin e should be easy to obtain; the cell line should be relatively easy to grow and maintain; there should be available data for the comparison of results; data and experiments should be easily reproducible; and comparable results using the cell line should be obtained across experiments and across laboratories. In addition to these properties, a reference standard should represent, as closely as possible, the normal or experimental cell line and a particular state of that cell line. In this grant application, we are proposing a reference standard for the undifferentiated hESC state. We propose that nullipotent 2102Ep is better representative of the undifferentiated hESC state than any non-hESC line. Currently, however, there is no commercial source of standardi zed 2102Ep. We propose to: 1. Perform side-by-side characterization and comparison of two clones of the human embryonal carcinoma cell line 2102Ep 2102Ep cl.4D3 and 2102Ep cl.2A6 - in order to determine which clone is best suited as a reference standard fo r the undifferentiated hESC state. The criteria used to determine which clone is best will be based on elevated, uniform expression of markers of the undifferentiated state. 2. Moderately scale-up best clone as determined in Specific Aim 1 to a working cel l bank; characterize working cell bank and compare results to those obtained in Aim 1. Characterization will examine the identity, stability, and marker expression of the two clones. The significance of this work is its general applicability to hESC resear ch and the benefit that will be reaped by the hESC research community once such a qualified reference standard is widely available.The end result and relevance of this project is a clone of human EC 2102Ep which closely represents the undifferentiated huma n ESC state. This clone will be produced under standardized conditions; it will be well-characterized, easy to use, and readily available. Availability of this clone is a necessary step to hasten the pace of sequential advances in hESC research.

Technology keywords

Not reported

Agency intelligence

Department of Health and Human Services

Back to SBIR/STTR Research Awards

Don't take our word for it. Ask AI about RFPCapture.

See what leading AI assistants have to say about RFPCapture and CaptureIQ.

Gemini opens without a prefilled question. The question is copied to your clipboard when the button works. You can also copy it here:

What is RFPCapture.com and its CaptureIQ platform from Smart Logic AI? How does it help federal contractors discover opportunities, evaluate bid/no-bid decisions, research government contracts, and prepare proposals? How does it compare with other federal capture platforms? Use independent sources where available.